S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.02 (-2.95%)
AAPL   122.04 (-2.46%)
MSFT   227.39 (-2.77%)
FB   255.41 (-1.39%)
GOOGL   2,014.74 (-2.41%)
TSLA   656.90 (-4.30%)
AMZN   3,011.00 (-2.70%)
NVDA   513.25 (-4.29%)
BABA   236.27 (+0.79%)
CGC   33.26 (-5.65%)
GE   13.44 (+3.54%)
MU   89.25 (-2.02%)
NIO   41.53 (-4.07%)
AMD   80.85 (-3.90%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   519.52 (-5.17%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.02 (-2.95%)
AAPL   122.04 (-2.46%)
MSFT   227.39 (-2.77%)
FB   255.41 (-1.39%)
GOOGL   2,014.74 (-2.41%)
TSLA   656.90 (-4.30%)
AMZN   3,011.00 (-2.70%)
NVDA   513.25 (-4.29%)
BABA   236.27 (+0.79%)
CGC   33.26 (-5.65%)
GE   13.44 (+3.54%)
MU   89.25 (-2.02%)
NIO   41.53 (-4.07%)
AMD   80.85 (-3.90%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   519.52 (-5.17%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.02 (-2.95%)
AAPL   122.04 (-2.46%)
MSFT   227.39 (-2.77%)
FB   255.41 (-1.39%)
GOOGL   2,014.74 (-2.41%)
TSLA   656.90 (-4.30%)
AMZN   3,011.00 (-2.70%)
NVDA   513.25 (-4.29%)
BABA   236.27 (+0.79%)
CGC   33.26 (-5.65%)
GE   13.44 (+3.54%)
MU   89.25 (-2.02%)
NIO   41.53 (-4.07%)
AMD   80.85 (-3.90%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   519.52 (-5.17%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.02 (-2.95%)
AAPL   122.04 (-2.46%)
MSFT   227.39 (-2.77%)
FB   255.41 (-1.39%)
GOOGL   2,014.74 (-2.41%)
TSLA   656.90 (-4.30%)
AMZN   3,011.00 (-2.70%)
NVDA   513.25 (-4.29%)
BABA   236.27 (+0.79%)
CGC   33.26 (-5.65%)
GE   13.44 (+3.54%)
MU   89.25 (-2.02%)
NIO   41.53 (-4.07%)
AMD   80.85 (-3.90%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   519.52 (-5.17%)
PFE   34.39 (+2.63%)
Log in
NASDAQ:SBTX

Silverback Therapeutics Competitors

$51.17
-1.63 (-3.09 %)
(As of 03/3/2021 03:59 PM ET)
Add
Compare
Today's Range
$50.90
Now: $51.17
$53.14
50-Day Range
$41.78
MA: $46.53
$52.03
52-Week Range
$24.22
Now: $51.17
$54.41
Volume5,694 shs
Average Volume185,404 shs
Market Capitalization$1.69 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Silverback Therapeutics (NASDAQ:SBTX) Vs. SANA, ABCM, SEER, CGEM, BCAB, and GRCL

Should you be buying SBTX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Silverback Therapeutics, including Sana Biotechnology (SANA), Abcam (ABCM), Seer (SEER), Cullinan Management (CGEM), BioAtla (BCAB), and Gracell Biotechnologies (GRCL).

Silverback Therapeutics (NASDAQ:SBTX) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Silverback Therapeutics and Sana Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Silverback TherapeuticsN/AN/AN/A
Sana BiotechnologyN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Silverback Therapeutics and Sana Biotechnology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Silverback Therapeutics00403.00
Sana Biotechnology02202.50

Silverback Therapeutics currently has a consensus target price of $46.25, indicating a potential downside of 9.62%. Sana Biotechnology has a consensus target price of $40.00, indicating a potential upside of 63.73%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Silverback Therapeutics.

Earnings and Valuation

This table compares Silverback Therapeutics and Sana Biotechnology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silverback TherapeuticsN/AN/AN/AN/AN/A
Sana BiotechnologyN/AN/AN/AN/AN/A

Summary

Silverback Therapeutics beats Sana Biotechnology on 2 of the 3 factors compared between the two stocks.

Silverback Therapeutics (NASDAQ:SBTX) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Silverback Therapeutics and Abcam's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Silverback TherapeuticsN/AN/AN/A
AbcamN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Silverback Therapeutics and Abcam, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Silverback Therapeutics00403.00
Abcam02302.60

Silverback Therapeutics currently has a consensus target price of $46.25, indicating a potential downside of 9.62%. Abcam has a consensus target price of $22.3333, indicating a potential upside of 0.78%. Given Abcam's higher probable upside, analysts clearly believe Abcam is more favorable than Silverback Therapeutics.

Earnings and Valuation

This table compares Silverback Therapeutics and Abcam's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silverback TherapeuticsN/AN/AN/AN/AN/A
AbcamN/AN/AN/AN/AN/A

Summary

Silverback Therapeutics beats Abcam on 2 of the 3 factors compared between the two stocks.

Silverback Therapeutics (NASDAQ:SBTX) and Seer (NASDAQ:SEER) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Silverback Therapeutics and Seer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Silverback TherapeuticsN/AN/AN/A
SeerN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Silverback Therapeutics and Seer, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Silverback Therapeutics00403.00
Seer02202.50

Silverback Therapeutics currently has a consensus target price of $46.25, indicating a potential downside of 9.62%. Seer has a consensus target price of $69.6667, indicating a potential upside of 39.25%. Given Seer's higher probable upside, analysts clearly believe Seer is more favorable than Silverback Therapeutics.

Earnings and Valuation

This table compares Silverback Therapeutics and Seer's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silverback TherapeuticsN/AN/AN/AN/AN/A
SeerN/AN/AN/AN/AN/A

Summary

Silverback Therapeutics beats Seer on 2 of the 3 factors compared between the two stocks.

Silverback Therapeutics (NASDAQ:SBTX) and Cullinan Management (NASDAQ:CGEM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Earnings and Valuation

This table compares Silverback Therapeutics and Cullinan Management's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silverback TherapeuticsN/AN/AN/AN/AN/A
Cullinan ManagementN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Silverback Therapeutics and Cullinan Management, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Silverback Therapeutics00403.00
Cullinan Management01302.75

Silverback Therapeutics currently has a consensus target price of $46.25, indicating a potential downside of 9.62%. Cullinan Management has a consensus target price of $48.00, indicating a potential downside of 8.57%. Given Cullinan Management's higher probable upside, analysts clearly believe Cullinan Management is more favorable than Silverback Therapeutics.

Profitability

This table compares Silverback Therapeutics and Cullinan Management's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Silverback TherapeuticsN/AN/AN/A
Cullinan ManagementN/AN/AN/A

Summary

Silverback Therapeutics beats Cullinan Management on 2 of the 3 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Earnings & Valuation

This table compares BioAtla and Silverback Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtlaN/AN/AN/AN/AN/A
Silverback TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for BioAtla and Silverback Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioAtla00403.00
Silverback Therapeutics00403.00

BioAtla currently has a consensus target price of $48.00, indicating a potential downside of 5.88%. Silverback Therapeutics has a consensus target price of $46.25, indicating a potential downside of 9.62%. Given BioAtla's higher probable upside, research analysts plainly believe BioAtla is more favorable than Silverback Therapeutics.

Profitability

This table compares BioAtla and Silverback Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioAtlaN/AN/AN/A
Silverback TherapeuticsN/AN/AN/A

Summary

BioAtla beats Silverback Therapeutics on 1 of the 1 factors compared between the two stocks.

Gracell Biotechnologies (NASDAQ:GRCL) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Gracell Biotechnologies and Silverback Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gracell Biotechnologies00403.00
Silverback Therapeutics00403.00

Gracell Biotechnologies currently has a consensus target price of $34.50, indicating a potential upside of 46.19%. Silverback Therapeutics has a consensus target price of $46.25, indicating a potential downside of 9.62%. Given Gracell Biotechnologies' higher probable upside, research analysts plainly believe Gracell Biotechnologies is more favorable than Silverback Therapeutics.

Earnings & Valuation

This table compares Gracell Biotechnologies and Silverback Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gracell BiotechnologiesN/AN/AN/AN/AN/A
Silverback TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Gracell Biotechnologies and Silverback Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gracell BiotechnologiesN/AN/AN/A
Silverback TherapeuticsN/AN/AN/A

Summary

Gracell Biotechnologies beats Silverback Therapeutics on 1 of the 1 factors compared between the two stocks.


Silverback Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SANA
Sana Biotechnology
1.3$24.43-22.2%$5.49 billionN/A0.00Analyst Report
Abcam logo
ABCM
Abcam
1.1$22.16-3.4%$5.20 billionN/A0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Gap Up
SEER
Seer
1.3$50.03-2.8%$3.13 billionN/A0.00Decrease in Short Interest
Gap Down
CGEM
Cullinan Management
1.0$52.50-0.4%$2.16 billionN/A0.00News Coverage
Gap Up
BCAB
BioAtla
1.6$51.00-1.7%$1.66 billionN/A0.00Increase in Short Interest
GRCL
Gracell Biotechnologies
1.7$23.60-2.1%$1.58 billionN/A0.00Upcoming Earnings
News Coverage
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.6$43.57-1.4%$1.55 billionN/A0.00Upcoming Earnings
News Coverage
VOR
Vor Biopharma
0.9$39.66-7.4%$1.52 billionN/A0.00Analyst Report
News Coverage
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$32.64-10.0%$1.40 billionN/A0.00Gap Up
KNTE
Kinnate Biopharma
2.0$34.26-3.2%$1.38 billionN/A0.00News Coverage
PHVS
Pharvaris
0.8$37.95-2.1%$1.23 billionN/A0.00Analyst Report
News Coverage
Gap Up
FDMT
4D Molecular Therapeutics
0.9$40.79-4.6%$1.08 billionN/A0.00Increase in Short Interest
Gap Up
SGTX
Sigilon Therapeutics
1.9$27.22-8.0%$887.28 millionN/A0.00Increase in Short Interest
Gap Up
PHAR
Pharming Group
0.0$13.55-0.8%$871.59 millionN/A0.00Increase in Short Interest
News Coverage
ANGN
Angion Biomedica
1.0$20.54-1.8%$600.27 millionN/A0.00Analyst Report
News Coverage
Inventiva logo
IVA
Inventiva
1.7$15.00-2.9%$592.79 millionN/A0.00
TERN
Terns Pharmaceuticals
1.3$24.86-3.1%$577.25 millionN/A0.00Analyst Report
News Coverage
Gap Down
LABP
Landos Biopharma
1.8$15.22-5.6%$562.77 millionN/A0.00Analyst Report
Analyst Revision
Gap Up
NEXI
NexImmune
0.3$23.75-2.6%$558.39 millionN/A0.00
SNSE
Sensei Biotherapeutics
2.0$15.82-1.8%$476.18 millionN/A0.00Analyst Report
Analyst Revision
Gap Down
DBTX
Decibel Therapeutics
0.3$18.00-0.4%$439.14 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.2$7.20-2.1%$388.91 millionN/A-3.83Upcoming Earnings
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$9.80-2.2%$344.71 millionN/A-3.87Gap Down
GMTX
FS Development
1.0$16.00-0.1%$248.72 millionN/A0.00Analyst Report
News Coverage
Gap Down
IPA
ImmunoPrecise Antibodies
0.0$12.98-7.9%$235.33 millionN/A0.00Decrease in Short Interest
Gap Up
NUVB
Nuvation Bio
0.0$11.00-1.3%$200.43 millionN/A0.00Gap Up
Annovis Bio logo
ANVS
Annovis Bio
0.0$27.51-3.1%$195.92 millionN/A0.00News Coverage
VINC
Vincerx Pharma
1.0$20.65-0.0%$169.43 millionN/A0.00Increase in Short Interest
LGVN
Longeveron
0.3$7.78-5.3%$153.21 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.0$7.22-7.3%$148.79 millionN/A0.00Analyst Report
News Coverage
IKT
Inhibikase Therapeutics
0.0$6.42-4.4%$67.34 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$15.76-6.2%$65.42 millionN/A0.00Upcoming Earnings
VIRI
Virios Therapeutics
1.3$5.93-5.7%$49.11 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$5.95-0.5%$40.40 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.41-3.2%$2.72 millionN/A0.00News Coverage
Gap Down
ADTX
ADiTx Therapeutics
1.0$3.09-4.2%$0.00N/A0.00Decrease in Short Interest
CBDC
Apotheca Biosciences
0.4$0.03-0.0%$0.00N/A0.00
CDMOP
Avid Bioservices
0.3$30.95-1.5%$0.00N/A0.00Increase in Short Interest
SCPS
Scopus BioPharma
1.4$8.92-0.4%$0.00N/A0.00Decrease in Short Interest
Gap Down
This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.